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Abstract
The GPR30 is a novel estrogen receptor (ER) that is a candidate membrane ER
based on its binding to 17b estradiol and its rapid signaling properties such as
activation of the extracellular-regulated kinase (ERK) pathway. Its distribution
in the mouse limbic system predicts a role for this receptor in the estrogenic
modulation of anxiety behaviors in the mouse. A previous study showed that
chronic administration of a selective agonist to the GPR30 receptor, G-1, in the
female rat can improve spatial memory, suggesting that GPR30 plays a role in
hippocampal-dependent cognition. In this study, we investigated the effect of a
similar chronic administration of G-1 on behaviors that denote anxiety in adult
ovariectomized female mice, using the elevated plus maze (EPM) and the open
field test as well as the activation of the ERK pathway in the hippocampus.
Although estradiol benzoate had no effect on behaviors in the EPM or the open
field, G-1 had an anxiolytic effect solely in the open field that was independent
of ERK signaling in either the ventral or dorsal hippocampus. Such an anxio-
lytic effect may underlie the ability of G-1 to increase spatial memory, by acting
on the hippocampus.
Introduction
Anxiety disorders encompass a wide range of disorders,
including panic disorders, obsessive-compulsive disorders,
posttraumatic stress disorders, and generalized anxiety
disorders (GAD) and have a 16% prevalence rate world-
wide (Somers et al. 2006). As the incidence of anxiety dis-
orders is twofold greater in females than males (Somers
et al. 2006) and arises during puberty (Hayward and
Sanborn 2002) (Angold and Worthman 1993), gonadal
hormones, particularly estrogens (Sachar et al. 1976;
Hamilton et al. 1984; Poromaa and Segebladh 2012), are
thought to modulate mood. In female rodents, a number
of studies have examined the effects of hormones using
the open field test (OFT), the elevated plus maze (EPM),
and the light–dark transition (LDT) test, which are para-
digms of unconditioned conflict anxiety that model GAD
(Uys et al. 2003). Proestrous rats (Frye et al. 2000) and
mice (Walf et al. 2009) were less anxious on the EPM
than diestrous animals suggesting that higher levels of
ovarian hormones exert anxiolytic effects (Marcondes
et al. 2001; Byrnes and Bridges 2006). However, this effect
appears to depend on estradiol dose, timing (Slater and
Blizard 1976), and even context. Although estradiol in
OVX rats was an anxiolytic in a nonsocial EPM task, it
exerted anxiogenic effects in a social interaction test with
a same-gender partner, suggesting that estradiol may be
an anxiolytic or an anxiogenic, depending on context
(Koss et al. 2004). Proestrous levels of estrogen generated
by a 25 lg estradiol benzoate (EB) implant in OVX
female mice also had anxiogenic effects in all three tests,
that is, the EPM, LDT test, and the OFT (Morgan and
Pfaff 2002). As these paradigms use chronic administra-
tion of estrogens, the classical estrogen receptor (ER) iso-
forms, ERa and ERb, are thought to slowly regulate
anxiety via transcription (Nilsson et al. 2001). However,
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administration of 10 lg/kg 17b estradiol exerted anxio-
lytic effects in the elevated T-maze within 30 min in OVX
rats (Kalandakanond-Thongsong et al. 2012), whereas
administration of 25 lg/kg 17b estradiol to female mice
was an anxiogenic in the EPM and open field (Kastenber-
ger et al. 2012) tasks within 2 h of a single injection.
These studies implicate a rapid, possibly nongenomic,
mode of signaling by 17b estradiol that contributes to
state anxiety. One candidate for nongenomic signaling by
17b estradiol is the GPR30, a former orphan G-protein
coupled receptor that binds 17b estradiol with a Kd value
of 6 nmol/L (Thomas et al. 2005). The expression of
GPR30 in the hippocampus and the central amygdala
(Hazell et al. 2009) suggests that this receptor contributes
to some of 17b estradiol’s effect on the limbic system. In
OVX rats, chronic administration of the specific GPR30
agonist, G-1 at 5 lg/day improved memory on a delayed
matching to place (DMP) task that requires hippocampal-
ly encoded spatial memory (Hammond et al. 2009). In
OVX acutely stressed mice, GPR30 expression increased
in the basolateral amygdala and G-1 regulated the NMDA
receptor system to increase inhibitory synaptic transmis-
sion (Tian et al. 2013), thus decreasing anxiety. Contrary
to this anxiolytic effect of GPR30 activation, Kastenberger
et al. (2012) showed that 1 mg/kg body weight of G-1
given 2 h before testing to OVX female mice increased
anxiety in the EPM and OFT, but not in the LDT. Hence,
similar to the studies that show both anxiolytic and anxi-
ogenic effects of 17b estradiol, GPR30 activation by the
use of a selective agonist also leads to differing effects on
state anxiety that are dependent on dose and timing.
As recent studies suggest that enhanced performance
on spatial tasks is correlated with lower anxiety (Kheirbek
et al. 2013; Olsen et al. 2013), we hypothesized that the
enhancement seen in the DMP task in OVX rats with
chronic administration of G-1 (Hammond et al. 2009)
could be due to an anxiolytic effect of GPR30 activation.
Hence, adult ovariectomized mice chronically adminis-
tered, via silastic implants, EB, G-1, or vehicle were tested
on the EPM task and the open field test. Our second
hypothesis was that the anxiolytic effect exerted by G-1
would correlate with increased extracellular-regulated
kinase (ERK) activation as well as the subsequent phos-
phorylation of an ERK target – the serine 118 of the ERa
itself (Kato et al. 1995) – in the hippocampus. This is
because GPR30 activation increased ERK activation in a
breast cancer (MCF-7) cell line (Filardo et al. 2000) and
ERK signaling elevates mood (Einat et al. 2003; Qi et al.
2009) and cognition (Fernandez et al. 2008); this would
then provide a molecular mechanism to explore in future
work. We show here that chronic administration of G-1,
but not EB, decreases anxiety in the OFT but not in the
EPM, independent of the regulation of ERK and the S118
site on the ERa in either the dorsal or ventral hippo-
campus.
Material and Methods
Animals
Adult, wild-type C57/Bl6 female mice (14–18 weeks of
age) were obtained from Charles River (Wilmington,
MA). Mice were individually housed under a 12:12
light–dark cycle, and food and water were provided ad
libitum. Cages were changed weekly and no more than
48 h before any test. All mice were ovariectomized under
isoflurane anesthesia and received an injection of Bupre-
nex (Reckitt Benckiser Pharmaceuticals, Inc., Richmond,
VA) for postoperative analgesia. All mice were allowed
to rest for 10 days following surgery to allow for recov-
ery from surgery and reduction in circulating hormone
levels. The weight of each mouse was tracked after each
behavioral test and before sacrifice. All living conditions
and tests were in accordance with the NIH Guide for
the Care and Use of Laboratory Animals and approved
by the Tulane University Institutional Animal Care and
Use Committee.
Hormone regimen
Ten days after OVX, mice were surgically implanted with
subcutaneous silastic capsules (1.57 mm ID 9 2.41 mm
OD 9 17 mm L; Dow Corning Corporation, Midland,
MI) containing 20 lL of sesame oil alone or 2 lg of EB
(Sigma-Aldrich Company, St. Louis, MO) or 10 lg of G-1
(Tocris, Bristol, U.K.) (n = 12/treatment group). These
numbers/treatment groups have been used in previous
studies (Kastenberger et al. 2012). Silastic capsule pre-
paration and implantation are performed as described in
Moffatt et al. (1998) and Ogawa et al. (2003). Mice were
allowed to recover for an additional 10 days before
behavioral testing to achieve constant steady-state level of
drug diffusion among treatment groups (Morgan and Pfaff
2002; Ogawa et al. 2003). All behavioral testing, once
initiated, was performed within 20 days of implantation.
Behavioral testing
All tests were conducted during the dark cycle, beginning
90 min after lights were turned off and after an acclima-
tion period of at least 2 h to the testing room. A 3-day
window was maintained between the EPM test and the
OFT in order to avoid intertest effects. This timeline and
method of testing follows previously published studies
(Tomihara et al. 2009). The testing room was dimly lit by
a red lamp with luminosity between 5 and 20 lux.
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Elevated plus maze
The EPM apparatus consisted of four arms (31.25 cm
L 9 5 cm W 9 14.5 cm H; Harvard Apparatus, Hollis-
ton, MA) at 90o angles to each other with all arm plat-
forms elevated 37.5 cm from the floor. At the start of a
trial, the mouse was placed in the center with its nose
directed toward the same closed arm and allowed to
explore the maze freely for 5 min. The total time spent,
total distance covered, and distance in and entries into
each arm and the center were digitally recorded by the
2100 Plus Tracking System (HVS Image Limited, Moun-
tain View, CA). Additional parameters determined in data
analysis were latency to the open arm, average speed, as
well as percentage of test time and distance spent in the
open and closed arms.
Open field
The OFT was utilized to examine locomotor activity as
well as anxious behavior. A 16-beam animal activity mon-
itor was used to divide the Plexiglass arena (40 cm
L 9 40 cm W 9 30 cm H) into center and periphery.
Fusion software (AccuScan Instruments Incorporated,
Columbus, OH) analyzed various parameters based on
recorded activity, including total distance, entries, rest
time, movement time, and latency to center and periph-
ery. The movement time is the time spent by the animal
moving, rather than freezing, in either the center or
periphery. At the beginning of each test, every animal was
introduced to the same corner (left back corner) of the
arena and was allowed to explore the arena freely for
5 min. Animals were tested twice on consecutive days on
the OFT to examine habituation.
Sample collection and western blotting
Two days after the last test, animals were deeply anesthe-
tized with isoflurane inhalation and rapidly decapitated.
The uteri from the animals were removed and collected in
preweighed tubes containing distilled water; wet weight
and images of the whole dissected uteri were recorded.
Dorsal and ventral hippocampus were dissected rapidly
and homogenized in RIPA lysis buffer (Boston Bioprod-
ucts, Ashland, MA) containing both protease and phos-
phatase inhibitors (Sigma Aldrich, St. Louis, MO). Protein
concentrations were determined by the Lowry assay (Bio-
Rad, Hercules, CA). Total protein of 20 lg was separated
with sodiumdodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE) using either 10% (for ERK and
GAPDH) or 7.5% (for ERa and a-tubulin) acrylamide
gels and then transferred to polyvinylidene difluoride
membranes (Millipore, Billerica, MA). Membranes were
blocked for 1 h at room temperature with 5% bovine
serum albumin (BSA) in Tris-buffered saline with 0.1%
Tween 20 (TTBS) followed by incubation with mild agita-
tion with the following primary antibodies diluted in
blocking buffer: antiphospho-p44/42 mitogen-activated
protein kinase Thr202/Tyr204 (1:2500; #4377, Cell Signal-
ing Technology, MA) for 1 h at room temperature, anti-
phospho-S118 ERa (1:5000; sc-12915-R, Santa Cruz
Biotechnology, CA) overnight at 4⁰C, anti-ERa (H-184)
(1:1000; sc-7207, Santa Cruz Biotechnology, CA) over-
night at 4⁰C, and anti-a tubulin (1:10,000; 1878-1, Epito-
mics, CA) for 1 h at room temperature. Following
primary incubation, blots were washed with TTBS and
incubated with anti-rabbit or anti-mouse horseradish per-
oxidase (HRP)-conjugated secondary antibody (1:20,000;
Cell Signaling Technology, MA) in 5% BSA/TTBS. Blots
were washed with TTBS and incubated with SuperSignal
West Femto Chemiluminescent Substrate (Thermo Scien-
tific Inc, IL) and chemiluminescence recorded with the
ChemiDoc XRS Imaging System (Bio-Rad Inc, CA). The
phospho-ERK antibodies was stripped with Tris-HCl with
2% SDS and 0.114M 2-mercaptoethanol preheated to 55⁰C
for 45 min. Stripped blots were again blocked in 5% BSA/
TTBS and reprobed with anti-ERK-1 C-16 (1:2500; sc-93,
Santa Cruz Biotechnology, CA) for 1 h at room tempera-
ture with mild agitation. Quantification of western blots
was performed using the Quantity One 1-D Image Analy-
sis Software (Bio-Rad). Integrated band intensity was cal-
culated for each phosphorylated and total protein band in
each lane and normalized to the GAPDH (for ERK kinase)
or a-tubulin (for S118 phosphorylated ERa and total ERa)
band within the lane for loading control. Experimental
values were normalized to the vehicle-treated samples
within the same blot for cross-blot comparison.
Statistical analysis
GraphPad Prism 5.04 (GraphPad Software Incorporated,
La Jolla, CA) was used to conduct all statistical analyses
and for graphs. For the EPM, all behavioral parameters
were analyzed for group differences using one-way analy-
sis of variance (ANOVA) followed by the Bonferroni’s
post hoc test. For the open field test, a repeated measures
2-way ANOVA was used to compare between treatment
group and day; Bonferroni’s post hoc test shows differ-
ences between groups. Animals that were found to be
outliers (defined as 2 SD from the mean) on multiple
parameters were removed from analysis of all data due to
the possibility that the implant may be the source of the
variation; hence, animal numbers are not equal across
treatment groups. In addition, Bartlett’s test for equal
variances was utilized to test for homogeneity for both
behavioral tests. For western blots, group differences in
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average vehicle-normalized band intensity values were
tested with one-way ANOVA followed by Tukey’s post
hoc test. Data are presented as mean  SEM and a
P < 0.05 was considered significant in all tests.
Results
Body weight and uterine weight
Animals were implanted with silastic capsules for 25 days
and the difference in body weight between implantation
and sacrifice was measured. EB-treated females were sig-
nificantly lighter than vehicle-treated females (Fig. 1A);
G-1-treated females were not significantly different from
either vehicle- or EB-treated groups. G-1-treated animals
also did not show any difference in uterine wet weight
compared to control vehicle-treated animals. EB-treated
animals showed a significant increase in uterine wet
weight compared to G-1-treated animals (Fig. 1B).
Behaviors that denote anxiety
In the EPM, there was no significant effect of treatment
on the percentage of time or distance spent in closed or
open arms (Fig. 2A and B). Across treatment groups, ani-
mals spent significantly more time and distance in closed
arms compared to open arms (Fig. 2A and B). In the
OFT, animals treated with G-1 moved a greater distance
in the center of the open field compared to those treated
with vehicle or EB (Fig. 3A). G-1-treated mice also spent
more time moving in the center (Fig. 3B), had a lower
latency to the center (Fig. 3C), and made more entries
into the center (Fig. 3D) than the EB-treated group. How-
ever, there were no differences in distance and movement
time in the periphery of the OFT by treatment group
(Fig. 3E and F). On the second day of OFT testing, mice
in all treatment groups traveled significantly less and spent
less time in the center of the open field compared to the
first day of testing (Fig. S1).
Protein analysis
We analyzed the activation of ERK1/2 by western blotting
using specific antibodies to the ERK 202/204 site; phosphory-
lation of this site is required for activation. We also investi-
gated phosphorylation at the serine 118 of the ERa using
specific antibodies. Although there was no difference among
treatment groups in the ventral hippocampus (Fig. 4A) in
pERK levels, there was an increase in pERK in the dorsal
hippocampus (Fig. 4B) in the EB-treated but not in the G-1-
treated group, compared to the vehicle-treated group. In the
ventral hippocampus but not in the dorsal hippocampus,
there was a small decrease in total ERa in the EB-treated
group compared to vehicle treatment (Fig. 5A); however,
there were no differences among treatment groups in the
phosphorylation of the ERK-dependent site at serine
118 (Fig. 5B) of the ERa in either the ventral or dorsal
hippocampus.
Discussion
Doses of estrogen and G-1
Doses of estradiol as well as routes of administration in
female rodents vary widely (Lund et al. 2005), depending
on the study’s endpoints. As we hypothesized that the
chronic G-1 effect on cognition (Hammond et al. 2009) is
linked to a possible anxiolytic effect of G-1, we chose an
EB dose and a route – that is, silastic capsules to obtain
steady-state levels – that could also lead to anxiolytic
behavior, as a comparison. Our dose of 2 lg EB/mouse
translates into roughly 70 lg/kg body weight, given a 30 g
mouse at the time of testing. As this dose promoted lordo-
sis in female mice when administered acutely 44 h before
(A) (B)
Figure 1. Estradiol benzoate (EB), but not G-1, decreases body weight but increases uterine weight. Animals were ovariectomized and implanted
with silastic capsules that administered vehicle (sesame oil), 2 lg EB, or 10 lg G-1 per mouse. Animals were sacrificed after the end of behavioral
testing and body and uteri weighed. Data represent mean  SEM. *P < 0.05 cf vehicle. #P < 0.05 cf G-1-treated group.
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testing (White et al. 2007), we know that this dose acts on
the brain. Also, OVX female rats administered EB doses
ranging from 1 lg/kg to 100 lg/kg body weight chroni-
cally by daily injection for 4 weeks did not show graded
anxiolytic responses in an elevated T-maze test that
mirrored generalized anxiety disorder (Kalandakanond-
Thongsong et al. 2012), suggesting that parameters that
denote anxiety may not be sensitive to dose. However, a
critical reason to choose lower rather than higher doses is
that very low doses ~0.1–0.2 lg/mouse per day adminis-
tered chronically had anxiolytic effects, whereas higher
doses exerted anxiogenic effects (Tomihara et al. 2009).
Our G-1 dose of 10 lg/mouse translates to about 330 lg/kg
body weight, given a 30 g mouse; this is around five times
more than the dose of EB/mouse. Although our chronic
administration route and dose is not directly comparable to
acute administration and dose of G-1 used in female mice
(Kastenberger et al. 2012), a similar ratio of G-1:estradiol was
used by Kastenberger et al. when acutely administering G-1
(at 1 mg/kg body weight) and 17b-estradiol (0.25 mg/kg
body weight) to female OVX mice (Kastenberger et al. 2012).
The GPR30 agonist, G-1, has been administered by s.c. injec-
tion to study acute effects (Kastenberger et al. 2012), and by
osmotic pumps (Hammond et al. 2009) to study chronic
effects. To the best of our knowledge, this is the first report
where G-1 was delivered via implantation of a silastic capsule
(A) (B)
Figure 2. Ovariectomized females treated chronically with either 17bE2 or G-1 were tested in the elevated plus maze. No significant effect of
treatment was found in either the time spent (Fig. 2A) or distance traveled (Fig. 2B) in either the open or closed arms. There was a significant
increase in the time spent (sec) and the amount of distance (m) traveled in the closed arms compared to open arms across treatment groups.
Data represent mean  SEM.
(A) (B) (C)
(D) (E) (F)
Figure 3. Ovariectomized females treated chronically with either 17bE2 or G-1 were tested in the open field arena. Mice treated chronically with
G-1, but not EB, displayed a reduction in anxiety-like behaviors, traveling larger distances (cm) in the center of the arena (Fig. 3A) compared to
vehicle and EB-treated mice (*P < 0.05), and more time (sec) moving in the center (Fig. 3B) compared to EB-treated mice (#P < 0.05). They also
had an almost significant (P = 0.06) lower latency to the center (Fig. 3C) of the open field and a greater number of entries (Fig. 3D) in the open
field than the EB-treated mice. No effect of treatment was revealed on the distance or time spent moving in the periphery. Data represent
mean  SEM.
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(A) (B)
Figure 4. Chronic G-1 treatment does not regulate ERK activation. Animals administered EB or G-1 chronically in silastic implants were sacrificed,
and western blot analysis on lysate from ventral hippocampus (A) and dorsal hippocampus (B) was performed. pERK is not regulated by hormone
treatment in either the ventral or dorsal hippocampus by G-1 (A and B), but pERK is upregulated by EB in the dorsal (B) but not in the ventral
hippocampus when compared to the vehicle-treated group. Data represent mean  SEM.
(A1) (B1)
(B2)(A2)
Figure 5. Although neither chronic EB nor G-1 treatment changed the phosphorylation at S118 in either the ventral hippocampus (A2) or dorsal
hippocampus (B2), EB treatment decreased the ERa concentration in the ventral hippocampus (A1) but not in the dorsal hippocampus (B1).
Animals were sacrificed and Western blotting analysis was performed on the lysate obtained from dorsal and ventral hippocampus. *P < 0.05 cf
vehicle treatment. Data represent mean  SEM.
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and had an effect on the central nervous system. As expected,
EB decreased body weight (Windahl et al. 2009) and
increased uterine wet weight (Gao et al. 2011); the lack of
effect of G-1 in the uterus has been noted previously (Gao
et al. 2011).
EPM versus OFT
Both EPM and OFT are widely used as tasks that
measure unconditioned avoidance of fearful situations
(Donner and Lowry 2013) and are thought to model gen-
eralized anxiety disorder or GAD (Uys et al. 2003). As
the cost of testing different groups of mice on each of the
tests would be prohibitive, the mice were tested on the
EPM first as it is the most sensitive test of anxiety
(Ramos 2008). No treatment showed any differences
when compared to vehicle in the EPM. However, surpris-
ingly, although OFT conducted under red light is not
deemed very fearful (DeFries et al. 1966), G-1 treatment
produced an anxiolytic effect in this test, as can be seen
by the greater distance and time spent in the center area
of the novel arena. The lack of effect of G-1 in the EPM
versus an anxiolytic effect in the OFT may be because of
several reasons. C57BL/6J females are typically more anx-
ious than males in the OFT (An et al. 2011), but less
anxious than males in the EPM (Voikar et al. 2001),
reflecting greater emotionality in the OFT rather than the
EPM, suggesting that this strain responds to a greater
extent in the OFT rather than the EPM. The effect of pre-
vious testing can also not be ruled out as individual ani-
mals could have different intrinsic anxiety at the time of
the EPM versus the OFT (Ramos 2008). A third reason
could be that the EPM and OFT may measure different
aspects of anxiety. Although a pharmacological approach
using benzodiazepine anxiolytics shows that both the
EPM (Pellow et al. 1985) and OFT (Prut and Belzung
2003) are responsive to these drugs that regulate the
GABAergic system, parameters that measure anxiety
loaded onto different factors when rats (Ramos et al.
1998) and mice (Trullas and Skolnick 1993) were tested
sequentially on the EPM and the OFT. Indeed, Ramos
et al. (2008) found that even when the three tests were
physically integrated into a single apparatus, the percent-
age of shared variance between paired variables such as
the distance in the center in the OFT and the time in the
open arms in the EPM was only 1.7%. Hence, these tests
may measure different aspects of emotionality in mice.
Finally, it is also possible that G-1 effect on anxiety is
due to its effect on peripheral systems such as the cardio-
vascular system (Deschamps and Murphy 2009), which
may influence state anxiety. The lack of EB regulation of
anxiety in either the EPM or OFT is unclear, although it
is possible that the EB effect in female mice may be more
apparent under more stressful conditions such as white
light, rather than the red light used in this study. Indeed,
isolation stress resulted in an anxiolytic effect in the LDT
but not in the EPM in female mice (Guo et al. 2004). In
addition, the lack of an effect of EB on the OFT could be
due to EB activation of multiple receptors that activate
opposing signaling pathways while G-1 selectively acti-
vates solely GPR30 to give an anxiolytic phenotype.
Signaling via ERK and ER
As ERK is involved in mood regulation (Einat et al. 2003)
(Qi et al. 2009) and GPR30 activation can increase ERK
signaling (Filardo et al. 2000), we hypothesized that regu-
lation of anxiety may correlate with ERK activation in the
ventral hippocampus as the ventral hippocampus is typi-
cally associated with anxiety (Alves et al. 2004). However,
neither ERK nor a downstream substrate of ERK – the ser-
ine residue at position 118 of the ERa – is regulated by
this dose of G-1 in either the dorsal or ventral hippocam-
pus. This could be because the dose dependence of behav-
ior versus that for signaling pathways could be different.
For example, the total ERa concentration in the ventral
hippocampus is decreased while the ERK activation in the
dorsal hippocampus increased by EB treatment despite
EB’s lack of significant effect on any of the parameters in
the EPM or the OFT. The ERK activation in the dorsal
hippocampus by EB has been demonstrated to be required
for learning in a novel object recognition task (Fernandez
et al. 2008); however, the changes are more likely due to
the hormone treatment as behaviors that denote anxiety in
the EB-treated group did not change. However, both the
increase in ERK and the decrease in ERa demonstrate that
the lack of behaviors that denote increased or decreased
anxiety in the EB-treated animals is not due to lack of EB
entering the brain. It is also possible that other pathways
activated by GPR30 such as protein kinase A (Thomas
et al. 2005) or other nuclei such as the basolateral amyg-
dala are important in anxiety regulation; these will be
investigated in future studies.
Summary
The anxiolytic effect seen with chronic GPR30 activation
in the OFT could be beneficial for the improvement in
cognition seen by other investigators (Hammond et al.
2009; Hammond and Gibbs 2011). The difference
obtained with the tests underscores the importance of
using more than one test in the investigation of state
anxiety and suggests that GPR30-driven effects might be
better revealed in females under less stressful conditions.
Hence, selective activation of this receptor in the central
nervous system is important for mood regulation.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Chronic EB or G-1 treatment does not affect
habituation to the open field over consecutive days. Ani-
mals administered EB or G-1 chronically in silastic
implants were tested on two consecutive days to investi-
gate habituation to the open field arena. Both movement
time (A) and distance (cm) decreased during Day 2 com-
pared to Day 1, irrespective of hormone treatment
(*P < 0.05 cf days). Data represent mean  SEM.
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